Key Points
- Chidozie Ugwumba, a major shareholder, sold 13,095 Clene shares on Dec. 31 at an average of $5.81 for $76,081.95, leaving him with 770,495 shares (a 1.67% ownership decline).
- The sale is part of a string of insider dispositions in late December and early January — including a large Dec. 3 sale of 56,577 shares for $444,695 — indicating significant recent insider selling.
- Clene shares are trading down (~1.7%), with a market cap of about $59.6M, negative earnings (P/E -1.70), and a consensus analyst rating of "Moderate Buy" with a $32.60 target.
Clene Inc. (NASDAQ:CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 4,015 shares of the company's stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $5.73, for a total value of $23,005.95. Following the completion of the sale, the insider owned 766,480 shares of the company's stock, valued at $4,391,930.40. This trade represents a 0.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.
Chidozie Ugwumba also recently made the following trade(s):
- On Wednesday, December 31st, Chidozie Ugwumba sold 13,095 shares of Clene stock. The stock was sold at an average price of $5.81, for a total value of $76,081.95.
- On Tuesday, December 30th, Chidozie Ugwumba sold 4,138 shares of Clene stock. The stock was sold at an average price of $6.03, for a total value of $24,952.14.
- On Monday, December 29th, Chidozie Ugwumba sold 8,096 shares of Clene stock. The stock was sold at an average price of $5.95, for a total value of $48,171.20.
- On Tuesday, December 23rd, Chidozie Ugwumba sold 6,831 shares of Clene stock. The stock was sold at an average price of $6.27, for a total value of $42,830.37.
- On Friday, December 26th, Chidozie Ugwumba sold 3,350 shares of Clene stock. The stock was sold at an average price of $6.32, for a total value of $21,172.00.
- On Wednesday, December 24th, Chidozie Ugwumba sold 1,490 shares of Clene stock. The shares were sold at an average price of $6.27, for a total transaction of $9,342.30.
- On Monday, December 22nd, Chidozie Ugwumba sold 4,367 shares of Clene stock. The shares were sold at an average price of $6.54, for a total value of $28,560.18.
- On Friday, December 19th, Chidozie Ugwumba sold 5,582 shares of Clene stock. The stock was sold at an average price of $6.45, for a total value of $36,003.90.
- On Wednesday, December 3rd, Chidozie Ugwumba sold 56,577 shares of Clene stock. The shares were sold at an average price of $7.86, for a total transaction of $444,695.22.
- On Thursday, December 18th, Chidozie Ugwumba sold 5,816 shares of Clene stock. The shares were sold at an average price of $6.33, for a total transaction of $36,815.28.
Clene Trading Down 1.7%
CLNN stock opened at $5.77 on Friday. The stock has a 50-day moving average price of $8.06 and a two-hundred day moving average price of $6.34. The stock has a market cap of $59.60 million, a PE ratio of -1.70 and a beta of 0.87. Clene Inc. has a 1 year low of $2.28 and a 1 year high of $13.50.
Clene (NASDAQ:CLNN - Get Free Report) last announced its earnings results on Thursday, November 13th. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.25). The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.06 million. On average, analysts forecast that Clene Inc. will post -5.19 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
CLNN has been the subject of a number of research reports. UBS Group reissued a "buy" rating on shares of Clene in a report on Wednesday, December 3rd. D. Boral Capital reissued a "buy" rating and issued a $23.00 price objective on shares of Clene in a research note on Wednesday, December 10th. Benchmark reaffirmed a "buy" rating on shares of Clene in a research note on Thursday, December 4th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Clene in a report on Tuesday, October 14th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Clene has an average rating of "Moderate Buy" and an average price target of $32.60.
Check Out Our Latest Stock Report on CLNN
Institutional Trading of Clene
Institutional investors and hedge funds have recently modified their holdings of the stock. Jones Financial Companies Lllp purchased a new position in shares of Clene in the third quarter worth about $29,000. Jane Street Group LLC bought a new position in shares of Clene during the 2nd quarter valued at $47,000. Lunt Capital Management Inc. increased its holdings in shares of Clene by 71.2% in the second quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company's stock worth $199,000 after buying an additional 21,217 shares during the period. Finally, Scoggin Management LP lifted its position in Clene by 42.8% in the second quarter. Scoggin Management LP now owns 142,750 shares of the company's stock valued at $558,000 after purchasing an additional 42,750 shares during the last quarter. 23.28% of the stock is owned by hedge funds and other institutional investors.
Clene Company Profile
(
Get Free Report)
Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company's flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene's platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.
Clene's lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple sclerosis (MS).
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
